Publications
Detailed Information
CD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jae Yeo | - |
dc.contributor.author | Jin, Dong-Hoon | - |
dc.contributor.author | Lee, Chang-Min | - |
dc.contributor.author | Jang, Min Ja | - |
dc.contributor.author | Shin, Hyo Seon | - |
dc.contributor.author | Kim, Kyung Yong | - |
dc.contributor.author | Lee, Won Bok | - |
dc.contributor.author | Lee, Wang Jae | - |
dc.contributor.author | Kim, Daejin | - |
dc.contributor.author | Park, Yeong-Min | - |
dc.contributor.author | Shin, Yong Kyoo | - |
dc.contributor.author | Kim, Sung Su | - |
dc.contributor.author | Chung, Yoon Hee | - |
dc.contributor.author | Lee, Sun Young | - |
dc.date.accessioned | 2012-07-10T02:20:15Z | - |
dc.date.available | 2012-07-10T02:20:15Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.citation | JOURNAL OF IMMUNOTHERAPY; Vol.33(5); 510-522 | ko_KR |
dc.identifier.issn | 1524-9557 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78689 | - |
dc.description.abstract | The requirement for CD4(+) T cells in priming and maintaining cytotoxic T-lymphocyte responses presents a long-standing paradox in cellular immunology. In this study, we used sequential coadministration of a DNA vaccine encoding an invariant (Ii) chain in which the class II-associated Ii-peptide region is replaced with CD4(+) T-helper epitope, PADRE [Pan human leukocyte antigen-DR reactive epitope (Ii-PADRE)] or BclxL with a DNA vaccine encoding Sig/E7/LAMP-1 to verify the role of CD4(+) T cells for the generation of effectors and memory E7-specific CD8(+) T-cell immune responses. Sequential vaccination, with Ii-PADRE + Sig/E7/LAMP-1 priming followed by BclxL + Sig/E7/LAMP-1 boosting led to generation of E7-specific CD8(+) T cells, and was nearly equivalent in effect to coadministration with Ii-PADRE+Sig/E7/LAMP-1 or Bcl-xL + Sig/E7/LAMP-1 at both prime and boost. The mice vaccinated with the Ii-PADRE+Sig/E7/LAMP-1 prime-Bcl-xL + Sig/E7/LAMP-1 boost regimen exhibited better long-term E7-specific immune responses and tumor prevention effects in vivo than the mice vaccinated with the reverse sequential coadministration. After CD4+ T-cell depletion, mice primed with Ii-PADRE+Sig/E7/LAMP-1 generated low numbers of E7-specific CD8(+) T cells and suppressed long-term memory CD8(+) T-cell response regardless of the sequence or combination of DNA vaccines administered. Mice primed with Bcl-xL + Sig/E7/LAMP-1 only suppressed long-term memory CD8(+) T-cell response after depletion of CD4(+) T cells before priming. Our findings suggest that activated CD4(+) T cells at prime phase are important to generate the antigen-specific CD8(+) T-cell immune responses and CD4(+) T cells, which are naive or activated, play a role to maintain the long-term memory responses. | ko_KR |
dc.description.sponsorship | Supported by the Korea Research Foundation Grant funded by the
Korean Government (KRF-2008-314-E00195). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | ko_KR |
dc.subject | DNA vaccine | ko_KR |
dc.subject | Bcl-xL | ko_KR |
dc.subject | prime-boost | ko_KR |
dc.subject | Ii-PADRE | ko_KR |
dc.subject | E7 | ko_KR |
dc.title | CD4(+) T(H)1 Cells Generated by Ii-PADRE DNA at Prime Phase Are Important to Induce Effectors and Memory CD8(+) T Cells | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박재여 | - |
dc.contributor.AlternativeAuthor | 진동훈 | - |
dc.contributor.AlternativeAuthor | 이창민 | - |
dc.contributor.AlternativeAuthor | 장민자 | - |
dc.contributor.AlternativeAuthor | 이선영 | - |
dc.contributor.AlternativeAuthor | 신효선 | - |
dc.contributor.AlternativeAuthor | 정윤희 | - |
dc.contributor.AlternativeAuthor | 김경용 | - |
dc.contributor.AlternativeAuthor | 김성수 | - |
dc.contributor.AlternativeAuthor | 이원복 | - |
dc.contributor.AlternativeAuthor | 신용규 | - |
dc.contributor.AlternativeAuthor | 이왕재 | - |
dc.contributor.AlternativeAuthor | 박영민 | - |
dc.contributor.AlternativeAuthor | 김대진 | - |
dc.identifier.doi | 10.1097/CJI.0b013e3181d75cef | - |
dc.citation.journaltitle | JOURNAL OF IMMUNOTHERAPY | - |
dc.description.citedreference | Kim D, 2008, GENE THER, V15, P677, DOI 10.1038/sj.gt.3303102 | - |
dc.description.citedreference | Kim DJ, 2007, HUM GENE THER, V18, P1129, DOI 10.1089/hum.2007.090 | - |
dc.description.citedreference | Hung CF, 2007, MOL THER, V15, P1211, DOI 10.1038/sj.mt.6300121 | - |
dc.description.citedreference | Tsen SWD, 2007, EXPERT REV VACCINES, V6, P227, DOI 10.1586/14760584.6.2.227 | - |
dc.description.citedreference | Mueller SN, 2006, J IMMUNOL, V176, P7379 | - |
dc.description.citedreference | Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825 | - |
dc.description.citedreference | HUNG CF, 2006, METH MOLEC MED, V127, P199 | - |
dc.description.citedreference | Peng SW, 2004, J VIROL, V78, P8468, DOI 10.1128/JVI.78.16.8468-8476.2004 | - |
dc.description.citedreference | Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317 | - |
dc.description.citedreference | Behrens GMN, 2004, J IMMUNOL, V172, P5420 | - |
dc.description.citedreference | Lin CT, 2003, MOL THER, V8, P559, DOI 10.1016/S1525-0016(03)00238-7 | - |
dc.description.citedreference | Kim TW, 2003, J IMMUNOL, V171, P2970 | - |
dc.description.citedreference | Kim TW, 2003, J CLIN INVEST, V112, P109, DOI 10.1172/JCI200317293 | - |
dc.description.citedreference | Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441 | - |
dc.description.citedreference | Ouaaz F, 2002, IMMUNITY, V16, P257 | - |
dc.description.citedreference | Medema JP, 2001, J EXP MED, V194, P657 | - |
dc.description.citedreference | den Boer AT, 2001, J IMMUNOL, V167, P2522 | - |
dc.description.citedreference | Allen TM, 2000, J IMMUNOL, V164, P4968 | - |
dc.description.citedreference | Chen CH, 2000, CANCER RES, V60, P1035 | - |
dc.description.citedreference | Josien R, 2000, J EXP MED, V191, P495 | - |
dc.description.citedreference | Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927 | - |
dc.description.citedreference | Ji HX, 1999, HUM GENE THER, V10, P2727 | - |
dc.description.citedreference | Kent SJ, 1998, J VIROL, V72, P10180 | - |
dc.description.citedreference | Klenerman P, 1998, NATURE, V394, P482 | - |
dc.description.citedreference | McMichael AJ, 1998, NATURE, V394, P421 | - |
dc.description.citedreference | Irvine KR, 1997, J NATL CANCER I, V89, P1595 | - |
dc.description.citedreference | Jaiswal AI, 1997, J IMMUNOL, V159, P2282 | - |
dc.description.citedreference | DONNELLY JJ, 1997, LIFE SCI, V60, P163 | - |
dc.description.citedreference | Cella M, 1996, J EXP MED, V184, P747 | - |
dc.description.citedreference | Lin KY, 1996, CANCER RES, V56, P21 | - |
dc.description.citedreference | KEENE JA, 1982, J EXP MED, V155, P768 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.